Products
Search Result
Home >

Products >

neurokinin a peptide online manufacturer Manufacturer

The search yielded  (5)  results

Porcine Neurokinin A Peptide Catalog Number KS061040 CAS 86933-74-6

Neurokinin A (Porcine),Catalog Number: KS061040,CAS NO.: 86933-74-6 Neurokinin A has various roles in the body. For example, it mediates contraction of the colon and mediates brachioconstriction through the non-adrenergic non-cholinergic nervous system.

Substance P Neuropeptide Peptides CAS 33507-63-0 Molecular Weight 1347.7

Substance P,CAS#: 33507-63-0 ,Molecular Weight:1347.7 Substance P (SP) is an important neuropeptide belonging to the tachykinin family. It acts as a neurotransmitter and neuromodulator. It is closely related to neurokinin A, both originating from the same precursor preprotachykinin A. It is released from the terminals of sensory nerves and is involved in inflammation and pain processes.

Substance P Inflammation Peptides Catalog Number KS063011 CAS 33507-63-0

Substance P,Catalog Number: KS063011,CAS NO.:33507-63-0 Substance P (SP) is an important neuropeptide belonging to the tachykinin family. It acts as a neurotransmitter and neuromodulator. It is closely related to neurokinin A, both originating from the same precursor preprotachykinin A. It is released from the terminals of sensory nerves and is involved in inflammation and pain processes.

Neurokinin B Neuropeptide Peptides Cas 86933-75-7

Neurokinin B,Molecular Weight:1210.44,Purity95%,Lyophilized Neuromedin K belongs to the tachykinin family and may play an important role in the olfactory, gustatory, visceral, and neuroendocrine processing information. In addition, it is a potent bronchioconstrictor and has neruomodulatory roles in various brain functions.

PEPTID APIS

The biological activity of peptides is extensive and important, and they can act on the endocrine system, digestive system, cardiovascular system and so on. Although the history of peptides as pharmaceuticals is relatively short, it develops rapidly and has become a hot spot in the market. In the past decades, the number of peptide medications entering the clinical stage has been increasing, such as Semaglutide, Vasopressin, Edotreotide, Thymopentin, etc. With the rapid

1